Personalizing carbamazepine therapy

Table 1 HLA alleles associated with carbamazepine-induced cutaneous adverse drug reactions

Population	Target allele	Type of cADR	Selectivity in cases^a	Odds ratio	Reference
Han Chinese in Taiwan	HLA-B1502*	SJS-TEN	59/60	1,357	[7]
		HSS	0/13	-	[7]
		MPE	1/18	-	[7]
	HLA-A3101*	SJS-TEN	1/60	-	[7]
		HSS	2/13	-	[7]
		MPE	6/18	17.5	[7]
Japanese	HLA-A3101*	SJS-TEN	5/6	33.9	[9]
		DIHS	21/36	9.5	[9]
		Other	19/35	8.0	[9]
European	HLA-A3101*	SJS-TEN	5/12	25.93	[5]
		HSS	10/27	12.41	[5]
		MPE	23/106	8.33	[5]
Thai	HLA-B1502*	SJS-TEN	37/42	54.76	[10]
Malaysian	HLA-B1502*	SJS-TEN	12/16	16.15	[11]

^aNumber of patients with the target allele/number of patients with type of cADR. cADR, cutaneous adverse drug reaction; DIHS, drug-induced hypersensitivity syndrome; HLA, human leukocyte antigen; HSS, hypersensitivity syndrome; MPE, maculopapular exanthema; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.

ISSN: 1756-994X